Most Popular in:

Medical Esthetics Treatments

Email This Item! Print This Item!

Botox Receives National Marketing Authorization to Treat Crow's-Feet Lines

Posted: January 9, 2014
Botox Receives National Marketing Authorization to Treat Crow's-Feet Lines

Today, Allergan, Inc. announced that Botox has received the license from the Medicines and Healthcare products Regulatory Agency (MHRA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines (crow's-feet lines) seen at maximum smile, either alone or when treated at the same time as glabellar (or frown) lines seen at maximum frown, in adult patients where these facial lines have an important psychological impact. This marketing authorization is specific to Allergan's botulinum toxin type A product and is based on Allergan's successful global Phase III clinical trial program in crow's-feet lines.

"This latest approval for Botox demonstrates Allergan's continued commitment to excellence in neuromodulator innovation and our long-term leadership in medical esthetics," said Paul Navarre, president of Allergan Europe, Africa & Middle East. "We are proud to deliver this important innovation to medical esthetics practitioners in the United Kingdom, allowing them for the first time to treat the glabellar and crow's-feet areas either alone or simultaneously."

The MHRA license for the use of Botox to treat crow's-feet lines is based on the results of two randomized, multi-center, placebo-controlled clinical studies involving more than 1,350 patients.1 These studies met their primary endpoint, demonstrating that patients who received treatment with Botox achieved none or mild lines according to investigator assessment at day 30, compared to those patients who did not receive botulinum toxin type A treatment and this significant reduction in the appearance of crow's-feet lines lasted an average of four months post-treatment.1 In general, patients treated with Botox reported that they looked younger and more attractive.1 In these studies, Allergan's botulinum toxin type A product was generally well tolerated.1 Like all medicines, Allergan's botulinum toxin type A product may cause side effects, although the incidence rate is variable. In general, adverse reactions occurred within the first few days following injection and were temporary.1

"Crow's-feet lines are amongst the top aging concerns for people in the United Kingdom and Europe. While these lines form a natural part of our eye expressions, over time they can become fixed or elongated even when our faces are relaxed, which can make us look tired or stressed," said David Eccleston, clinical director, MediZen Clinic. "Softening the appearance of crow's-feet lines as well as the glabellar lines with Botox can deliver a refreshed and natural look, helping patients to look like themselves again and improve their self confidence."

© Allergan, Ltd. BOTOX® is a registered trademark owned by Allergan Inc.

References

  1. UK SmPC for BOTOX® 50 Units
  2. Stotland MA et al. J Plas Recons Surg: 2007; 120(5):1386-1393
  3. Allergan Data On File

 

Aesthetics Exposed: Mastering Skin Care in a Medical Setting and Beyond

This book answers your questions about the legalities of aesthetics, challenging skin concerns, skin care treatments, laser and light therapy, working with medical staff, innovative skin rejuvenation techniques and landing your dream job. If you are serious about advancing yourself and are self-motivated, this book is your first step in the right direction. You have to start somewhere.

Procedures! Complimenting Medical Procedures with Skin Care such as Neurotoxins, Soft Tissue Fillers, Facial Cosmetic Surgery

Techniques! Innovative Skin Rejuvenation Techniques such as Devices, Effective Formulations and Breakthrough Ingredients and Focusing on the Eyes

Treatments! Professional Skin Care Treatments such as Chemical Exfoliation, Microdermabrasion and Dermaplaning

More Treatments! Aesthetically Challenging Skin Concerns such as Acne, Rosacea and Aging Skin

Order Today at Amazon.com/!